TaiRx Inc
TPEX:6580
Decide a qué precio te sentirías cómodo comprando y te ayudaremos a estar preparado.
|
T
|
TaiRx Inc
TPEX:6580
|
TW |
|
P
|
Panin Financial Tbk PT
XMUN:OHH
|
ID |
|
C
|
Charn Issara Development PCL
SET:CI
|
TH |
|
Tryg A/S
CSE:TRYG
|
DK |
|
Dovalue SpA
MIL:DOV
|
IT |
Valor intrínseco
No hay suficientes datos para calcular de forma fiable el valor intrínseco de TaiRx Inc.
¿Nuestras valoraciones funcionan de verdad? Ver resultados del backtest .
Análisis fundamental
Qué hace TaiRx
TaiRx, Inc. engages in the research and development of novel drug products for cancer treatment. The company is headquartered in Taipei City, Taipei. The company went IPO on 2017-06-20. The firm primarily focus on the research and development of cancer treatment drugs and sepsis adjuvant therapy drugs. The firm's main products include CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, TRX-105 and others. CVM-1118 and Rexis are in clinical trials, and Zelnite drugs are sold to domestic medical institutions at all levels through distributors.
- Sede central
- Taiwán TW
- Fecha de salida a bolsa
- 20 jun., 2017